BioPorto Shows Strong Performance in Q3 Financial Results
BioPorto A/S, a leading in vitro diagnostics company, recently shared its interim financial results, marking notable progress through the third quarter. The company continues to emphasize its mission to enhance kidney health with innovative products, particularly in light of their growing NGAL sales.
Overview of Financial Growth
The latest report showcases that revenue for the third quarter of 2025 reached DKK 10.4 million. This figure reflects a 7% growth compared to the same time last year, displaying a healthy upward trend in the company’s sales. At constant exchange rates, the increase jumps to 10%. For the first nine months of 2025, BioPorto recorded total revenue of DKK 28.7 million, indicating a modest 1% increase year-over-year.
NGAL Sales Performance
In terms of NGAL, the heart of BioPorto’s operations, sales hit DKK 7.2 million in the third quarter. This represents a 5% growth compared to the previous year, with an impressive 10% growth when adjusted for exchange rates. As the company moves forward, NGAL continues to be pivotal in its business strategy, aiding in the diagnosis of acute kidney injury (AKI).
Strategic Milestones and New Developments
BioPorto has adopted a renewed strategy called “Forward,” focusing on market adoption and expanding its addressable market. A significant accomplishment occurred when the first ProNephro AKI™ (NGAL) order was successfully delivered to the U.S. market, marking a crucial step in the company's commercial rollout.
Clinical Trials and FDA Submissions
By the end of October 2025, patient enrollment in a pivotal clinical study was successfully completed. BioPorto has announced its intention to engage with the FDA for a pre-submission meeting, ensuring that its clinical validation study aligns closely with regulatory expectations. Initially projected for completion by the end of 2026, the submission timeframe has now been adjusted to the first half of 2027. This timeline underscores the company’s commitment to the highest quality research.
Financial Projections and Investor Insights
BioPorto’s financial outlook remains optimistic. The company has set a full-year revenue target between DKK 40-45 million, alongside an expected adjusted EBITDA loss ranging between DKK 75-80 million for 2025. The robust financial foundation is supported by a recent fully subscribed private placement that generated approximately DKK 43 million, bolstering the company's ambitions for positive cash flow.
Leadership Insights
Carsten Buhl, BioPorto’s CEO, has expressed confidence in the company’s trajectory, highlighting the importance of quality data analysis for successful product validation. He emphasized that the strategy aligns with efforts to transform kidney care worldwide, assuring stakeholders of the company’s dedication to innovation and improving patient outcomes.
About BioPorto and Its Mission
BioPorto is dedicated to enhancing the quality of life for patients through actionable kidney biomarkers that help clinicians in patient management. Their flagship product, the NGAL test, plays a crucial role in early detection of acute kidney injury, enabling timely interventions that can significantly impact patient care.
The company operates on a global scale, with facilities situated in Copenhagen and Boston. BioPorto's shares are publicly traded on the Nasdaq Copenhagen exchange under the ticker CPH:BIOPOR, making it accessible to a broad base of investors eager to support advancements in healthcare.
Frequently Asked Questions
What is BioPorto's main product focus?
BioPorto focuses on in vitro diagnostics, particularly through its NGAL biomarkers used for assessing kidney health and managing acute kidney injury.
What are the recent financial achievements of BioPorto?
For the third quarter of 2025, BioPorto reported revenues of DKK 10.4 million, showing a 7% year-over-year increase.
When does BioPorto expect to submit to the FDA?
BioPorto plans to submit its clinical validation data to the FDA in the first half of 2027 after thorough data analysis.
How is BioPorto supporting its financial growth?
The company recently completed a private placement that raised approximately DKK 43 million to support its operations and growth plans.
Where are BioPorto's operational facilities located?
BioPorto has operational facilities in both Copenhagen, Denmark, and Boston, Massachusetts, USA.
